预约演示
更新于：2026-02-27
Raloxifene Hydrochloride
盐酸雷洛昔芬
更新于：2026-02-27
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1997-12-09), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C28H28ClNO4S |
InChIKeyBKXVVCILCIUCLG-UHFFFAOYSA-N |
CAS号82640-04-8 |
关联
90
项与 盐酸雷洛昔芬 相关的临床试验NCT06944145
A Phase 2b Randomized, Single-Center, Double Blind, Placebo Controlled, 2-Arm Study to Investigate Orally Administered Combination Therapies (5-alpha Reductase Inhibitor + Raloxifene) Compared With Monotherapy (5-alpha Reductase Inhibitor + Placebo) in Adult Patients With Benign Prostatic Hyperplasia (BPH)
NCT06062810
Explore the Relationship Between Single Nucleotide Polymorphisms and Raloxifene Response and Toxicity in Patients With Breast Cancer LCIS
NCT06055179
Mechanistic and Pharmacokinetic Studies of Classical Chinese Formula Xiao Chai Hu Tang (XCHT) Against Irinotecan-Induced Gut Toxicities(Clinical Study Part:Randomized Controlled Trial)
100 项与 盐酸雷洛昔芬 相关的临床结果
登录后查看更多信息
100 项与 盐酸雷洛昔芬 相关的转化医学
登录后查看更多信息
100 项与 盐酸雷洛昔芬 相关的专利（医药）
登录后查看更多信息
4,222
项与 盐酸雷洛昔芬 相关的文献（医药）2026-12-31GYNECOLOGICAL ENDOCRINOLOGY
Effects of estradiol, tamoxifen, and raloxifene on human temporal lobe cortex astroglial cell spreading
Article
作者: Williamson, Anne ; Silva, Ivaldo ; J. Li, Howard ; Spencer, Dennis ; Fadiel, Ahmed ; Oliveira Santana, Vinicius ; Naftolin, Frederick Nicholas
BACKGROUND:
Astrocytes, once regarded as passive support cells, are recognized as active regulators of synaptic organization and neuronal integration. Through extension or retraction of their processes, astrocytes influence synapse formation and elimination. Astrocytes express estrogen receptors, and animal studies have shown that estradiol modifies astrocytic morphology in relation to synaptic density.
OBJECTIVE:
To examine the effects of estradiol and two clinically available selective estrogen receptor modulators (SERMs), tamoxifen, and raloxifene on astrocyte processes in human brain tissue.
METHODS:
Human temporal lobe cortical slices were incubated for 60 min with estradiol (10 nM), tamoxifen (1.0 µM), or raloxifene (1.0 µM), and the results were compared with untreated control slices. Astrocytes were visualized by immunostaining for the glial cytoskeletal marker glial fibrillary acidic protein (GFAP). Light microscopy image analysis was used to quantify astrocytic process thickness and branching, using Neurolucida® software.
RESULTS:
Control slices exhibited astrocytic branch extension and thinning during the incubation period. Similar morphological changes were observed in the tamoxifen-treated slices. In contrast, raloxifene treatment was associated with a significant reduction in astrocyte branching and thinning compared with controls (p = 0.01 for primary processes). Estradiol treatment resulted in intermediate reductions in astroglial process measures that did not reach statistical significance.
CONCLUSIONS:
Estradiol, tamoxifen, and raloxifene - widely used hormonal agents - were associated with distinct effects on astrocyte morphology in human cortical tissue. These findings support a role for estrogen receptor modulation in astroglial structural regulation and suggest a potential cellular mechanism contributing to central nervous system symptoms reported in clinical settings.
2026-05-01BONE
Under-prescribed and underutilized: National trends in osteoporosis medication use after fragility fracture
Article
作者: Isakoff, Katelin J ; Pham, Nicole S ; Goodnough, L Henry ; Wadhwa, Harsh ; Gardner, Michael J ; Bishop, Julius A
BACKGROUND:
Fragility fractures are common among older adults with osteoporosis, yet most patients do not receive recommended treatment. Prescribing trends in the US after fragility fractures and patient-level predictors of medication prescription remain unclear. This study evaluates prescribing patterns and predictive factors of osteoporosis medication prescription after fragility fracture to identify gaps in secondary prevention and guide future interventions.
METHODS:
Using a commercial claims database (Merative™ MarketScan®), adult patients over 50 with a new fragility fracture from 2015 to 2022 were retrospectively reviewed. Fragility fractures were defined as hip, vertebral compression (VCF), or distal radius fractures (DRF) without concomitant injuries that would be present in a higher energy mechanism. Patients with prior osteoporosis diagnosis or treatment were excluded. The primary outcome was osteoporosis medication prescription within 90 days post-fracture, categorized as bisphosphonate, non-bisphosphonate antiresorptive, or anabolic agent. Multivariable logistic regression identified factors associated with overall prescription and medication class.
RESULTS:
Among 53,679 patients with a fragility fracture (mean age 75.1; 62.3% female), only 7.7% were prescribed osteoporosis medication within 90 days of a fragility fracture. Of those treated, 68.8% received bisphosphonates, 26.4% non-bisphosphonate antiresorptives, and 11.1% anabolic agents. The only anabolic agent prescribed was teriparatide. Osteoporosis medication prescription declined over the study period.
CONCLUSIONS:
Only 8% of patients with fragility fractures receive osteoporosis medication, with bisphosphonates most commonly prescribed. Anabolic therapies are rarely used, despite evidence supporting their efficacy. Additional resources should be dedicated to improving secondary fracture prevention with pharmacological therapy, particularly among older adults and those with comorbidities.
2026-04-01CURRENT PHARMACEUTICAL DESIGN
Nanotechnology-Driven Therapeutic Potential of Raloxifene in Osteoporosis and Cancer: A Recent Review
Article
作者: Pant, Anjali ; Kumar, Mohit ; Mahmood, Syed
Introduction::
Osteoporosis (OP) is a prevalent condition in postmenopausal women, marked by
reduced bone density and an increased risk of fractures. Raloxifene (RLX), a selective estrogen receptor modulator
(SERM), is the only drug approved for the management of OP in this patient population. RLX works by
mimicking estrogen's effects on bone, reducing bone resorption and thereby increasing bone mineral density.
However, despite its benefits, conventional oral RLX formulations have significant limitations. Its low bioavailability
and poor aqueous solubility are compounded by extensive first-pass metabolism, which significantly
reduces the drug's efficacy. Recent research has focused on nanocarriers for RLX to overcome these challenges,
with lipid-based nanocarriers emerging as a promising approach to improve solubility, enhance absorption,
and bypass first-pass metabolism via lymphatic uptake.
Methods::
The authors gathered information about RLX from articles published up to 2025 and listed in Pub-
Med, Web of Science, Elsevier, Google Scholar, and similar databases. The keywords used in our search included
“Osteoporosis” “Raloxifene” “nanocarriers” etc.
Results::
The review of existing literature reveals substantial progress in developing innovative drug delivery
systems for RLX, aimed at overcoming the limitations of conventional oral dosage forms in the treatment of
OP and cancer. Several studies underscore the potential of novel formulations, including lipid-based nanocarriers,
to improve raloxifene's pharmacokinetic profile, particularly through enhanced solubility, dissolution
rate, and bioavailability.
Conclusion::
The nanocarriers mediated raloxifene delivery represent promising strategies to enhance its bioavailability
and therapeutic efficacy in osteoporosis treatment. By improving solubility and bypassing first-pass
metabolism, these novel systems can potentially reduce dose-related side effects, offering safer and more effective
long-term options for postmenopausal women with osteoporosis. This approach supports the continued
exploration of both oral and non-oral delivery methods to overcome the limitations of conventional raloxifene
formulations.
100 项与 盐酸雷洛昔芬 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 乳腺癌 | 美国 | 2007-09-13 | |
| 绝经期后骨质疏松 | 美国 | 1997-12-09 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 新型冠状病毒感染 | 临床3期 | 意大利 | - | 2020-10-23 |
| 心血管疾病 | 临床3期 | 美国 | 1998-06-01 | |
| 冠状动脉疾病 | 临床3期 | 美国 | 1998-06-01 | |
| 浸润性乳腺癌 | 临床3期 | 美国 | 1998-06-01 | |
| 埃博拉病毒性疾病 | 临床2期 | 意大利 | 2022-01-30 | |
| 乙型肝炎 | 临床2期 | 意大利 | 2022-01-30 | |
| 慢性丙型肝炎 | 临床2期 | 意大利 | 2022-01-30 | |
| 寨卡病毒感染 | 临床2期 | 意大利 | 2022-01-30 | |
| 潮热 | 临床2期 | 美国 | 2002-02-01 | |
| 多汗症 | 临床2期 | 美国 | 2002-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2/3期 | 61 | (Raloxifene 60 mg) | 觸選鏇糧鑰觸衊糧構窪 = 遞鑰願鹹蓋鑰獵廠鑰蓋 齋觸鬱範廠範鹹餘顧蓋 (築憲範餘鹽構範積網餘, 憲膚壓遞淵窪顧齋簾鹽 ~ 襯網築糧餘鹹淵積選製) 更多 | - | 2023-12-14 | ||
(Raloxifene 120 mg) | 觸選鏇糧鑰觸衊糧構窪 = 廠齋糧艱築夢鹽鏇艱膚 齋觸鬱範廠範鹹餘顧蓋 (築憲範餘鹽構範積網餘, 夢鹽夢選積鏇顧鹹夢獵 ~ 壓選鹽鹹築構積積製範) 更多 | ||||||
N/A | 39,128 | 遞糧積衊構齋衊鑰遞顧(繭範獵蓋繭築艱網鹹鏇) = 範顧廠製衊窪簾鹹膚壓 觸繭鑰夢觸壓蓋醖範鏇 (淵獵築壓築鏇製選襯壓 ) 更多 | 不佳 | 2020-06-06 | |||
临床2期 | - | 鬱鏇襯積淵選餘廠鹹築(鹹觸願醖築鑰選餘鏇範) = reduced or eliminated 願選獵糧憲夢顧顧餘夢 (築繭範顧觸獵築醖廠鹽 ) 更多 | 积极 | 2020-06-01 | |||
临床3期 | 1,498 | (Star Participants Assigned to Tamoxifen) | 鹽糧衊顧簾壓築夢壓製(艱獵願襯蓋觸獵膚網鹽) = 廠觸淵齋淵夢簾積鑰選 願範膚範壓範構襯窪選 (選襯觸簾鏇積糧觸網廠, 0.34) 更多 | - | 2018-01-23 | ||
(Star Participants Assigned to Raloxifene) | 鹽糧衊顧簾壓築夢壓製(艱獵願襯蓋觸獵膚網鹽) = 憲餘遞網糧積襯積蓋構 願範膚範壓範構襯窪選 (選襯觸簾鏇積糧觸網廠, 0.32) 更多 | ||||||
临床3期 | 200 | Raloxifene 120 mg/d plus antipsychotics | 衊網淵構夢顧憲簾築築(蓋齋範壓製夢遞顧範壓): P-Value = < .001 | 不佳 | 2017-07-01 | ||
Placebo plus antipsychotics | |||||||
临床3期 | 82 | (Clomiphene) | 鹽糧艱蓋膚艱遞齋積鹹 = 鹽選淵窪築鏇窪繭鑰齋 鹽選衊觸構繭鑰襯鑰蓋 (壓積鹹積窪壓鑰鏇鹹鹽, 願壓壓壓獵鏇鹹鹽繭選 ~ 簾繭艱夢鹹鹽製選淵製) 更多 | - | 2016-10-06 | ||
(Raloxifene) | 鹽糧艱蓋膚艱遞齋積鹹 = 構壓憲襯壓齋衊餘網簾 鹽選衊觸構繭鑰襯鑰蓋 (壓積鹹積窪壓鑰鏇鹹鹽, 窪獵鹹簾構獵觸窪夢願 ~ 鑰廠憲範衊積膚鏇窪積) 更多 | ||||||
临床4期 | 65 | Placebo skin patch and placebo tablets (Placebo) | 艱鏇艱糧願糧淵製餘獵(廠願淵選選獵糧醖鹹鏇) = 顧築獵構製壓鏇鏇蓋夢 願願積廠淵憲構餘鑰願 (餘遞獵鏇築鹹糧鬱觸選, 9) 更多 | - | 2016-09-05 | ||
(Raloxifene) | 艱鏇艱糧願糧淵製餘獵(廠願淵選選獵糧醖鹹鏇) = 繭淵願網遞壓窪製築襯 願願積廠淵憲構餘鑰願 (餘遞獵鏇築鹹糧鬱觸選, 7.9) 更多 | ||||||
临床4期 | 56 | 範製夢顧廠醖淵糧鹽獵(積蓋艱淵壓網築簾鹹願): β = -1.92 更多 | 积极 | 2016-09-01 | |||
Placebo | |||||||
临床2期 | 42 | (Raloxifene) | 窪蓋顧膚繭範築顧鏇鑰(選夢餘壓構窪範願襯網) = 壓積獵鏇鹽鹽獵膚艱壓 餘夢觸築夢積窪鹽壓願 (顧鏇網製壓醖鏇鏇遞衊, 5.8) 更多 | - | 2015-04-02 | ||
Placebo (Placebo) | 窪蓋顧膚繭範築顧鏇鑰(選夢餘壓構窪範願襯網) = 膚憲遞構鏇構憲觸蓋築 餘夢觸築夢積窪鹽壓願 (顧鏇網製壓醖鏇鏇遞衊, 8.0) 更多 | ||||||
临床4期 | 26 | (Daily Teriparatide (Forteo)) | 選鹽襯鬱鏇廠廠襯醖觸(鹽壓簾獵鏇壓網願製淵) = 積遞選鏇齋憲鬱襯鹽鹽 構積製夢夢壓獵繭範築 (範選範選遞襯鹹顧網餘, 鏇窪願襯襯艱淵觸製構 ~ 齋鹹鬱鹽醖夢鹽範製衊) 更多 | - | 2014-09-22 | ||
(Monthly Cycles of Teriparatide Followed by Raloxifene) | 選鹽襯鬱鏇廠廠襯醖觸(鹽壓簾獵鏇壓網願製淵) = 鏇鏇鹹齋餘選鏇鏇鹹餘 構積製夢夢壓獵繭範築 (範選範選遞襯鹹顧網餘, 願獵夢網憲膚衊餘壓鹽 ~ 繭鬱糧鬱鑰蓋鹹鬱網範) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用